Neuropathology of Parkinson disease

Dickson, Dennis W.·2018·Parkinsonism & Related Disorders

Cited by (623)

Items 401–500 of 623

  1. The Syn-D study: detection of cutaneous phosphorylated alpha-synuclein in mild cognitive impairment a trial protocol
    Christopher H. Gibbons, Douglas R Galasko, Daniel Zvi Press, Daniel O. Claassen, Todd Levine, Roy L. Freeman · 2025 · Biomarkers in Medicine
  2. Investigating the Effectiveness of Haptic Resistive Force Feedback to Improve Tremors in Parkinson’s Disease: A Training Impact Study
    Nafees Mahmood, Meldin Bektic, Chen Li, Angela L. Ridgel, Kwangtaek Kim · 2025 · IEEE Journal of Biomedical and Health Informatics
  3. Decoding synaptic imbalance in neurodegenerative diseases: From pathological analysis to targeted intervention
    Xiaodong Li, Rui Wan, Yang Zhao, Yumeng Wu, Xuehua Chen, Qianqian Li, Chengliang Luo · 2026 · Ageing Research Reviews
  4. Multi-Modal Synergistic 99mTc-TRODAT-1 SPECT and MRI for Evaluation of the Efficacy of Hyperbaric Oxygen Therapy in CO-Induced Delayed Parkinsonian and Non-Parkinsonian Syndromes
    Skye Hsin‐Hsien Yeh, Chuang‐Hsin Chiu, Hung‐Wen Kao, Ching‐Po Lin, Yu-Hus Lai, Wen-Sheng Huang · 2022 · Antioxidants
  5. Byrsonima sericea Ethanol Extract Protected PC12 Cells from the Oxidative Stress and Apoptosis Induced by 6-Hydroxydopamine
    Albert Layo Costa de Assis, Patrícia de Araújo Rodrigues, Selene Maia de Morais, Ana Lívya Moreira Rodrigues, Jessica Maria Pessoa Gomes, Tyciane de Souza Nascimento, Alfaete Vieira Oliveira, Mayara Sandrielly Pereira Soares, Geanne Matos de Andrade · 2023 · Neurochemical Research
  6. Comparative rhythmic transcriptome profiling of human and mouse striatal subregions
    Kaitlyn A. Petersen, Wei Zong, Lauren M. DePoy, Madeline R. Scott, Vaishnavi G. Shankar, Jennifer N. Burns, Allison J. Cerwensky, Sam-Moon Kim, Kyle D. Ketchesin, George C. Tseng et al. · 2024 · Neuropsychopharmacology
  7. Unveiling autonomic failure in synucleinopathies: Significance in diagnosis and treatment
    Gautier Clément, G. Cavillon, Fabrice Vuillier, Malika Bouhaddi, Matthieu Béreau · 2024 · Revue Neurologique
  8. The HALP score differs among sporadic and familial Parkinson's disease
    Wen Zhou, Qingqing Xia, Duan Liu, Jun Ying Li, Liang Gong · 2025 · Parkinsonism & Related Disorders
  9. A Mendelian randomization study on association of alpha-synuclein and GPNMB with Parkinson’s disease risk and progression
    Lizhi Li, Jiabin Liu, Yige Wang, Zhenhua Liu, Qian Xu, Xinxiang Yan, Beisha Tang, Jifeng Guo · 2025 · Molecular Neurobiology
  10. Does resistance training reduce falls and improve quality of life in people with Parkinson’s disease using strength training exercise programmes?
    Julian Chamberlain-Carter, Jo Jackson · 2020 · Physical Therapy Reviews
  11. Neuronal Dynamics of Pain in Parkinson’s Disease
    Kaoru Kinugawa, Tomoo Mano, Kazuma Sugie · 2021 · Brain Sciences
  12. Analysis of Impulse Control Disorders (ICDs) and Factors Associated with Their Development in a Parkinson’s Disease Population
    Mauricio Iván García-Rubio, María Elisa Otero Cerdeira, Christian Gabriel Toledo-Lozano, Sofía Lizeth Alcaráz‐Estrada, Juan Antonio Suárez‐Cuenca, Ramón Mauricio Coral‐Vázquez, Paul Mondragón‐Terán, Juan Antonio Pineda-Juárez, Luis Fernando Díaz-López, Silvia Garcı́a · 2021 · Healthcare
  13. Effects of Brain Factor‑7® against motor deficit and oxidative stress in a mouse model of MPTP‑induced Parkinson's disease
    Tae-Kyeong Lee, Jae‐Chul Lee, Dae Kim, Ji‐Won Lee, Sung‐Su Kim, Hyung Il Kim, Myoung Cheol Shin, Jun Cho, Moo‐Ho Won, Soo Young Choi · 2022 · Experimental and Therapeutic Medicine
  14. Immunohistochemical Analysis of Mitochondrial Ferritin in the Midbrain of Patients with Parkinson’s Disease
    Haruka Tsubaki, Daijiro Yanagisawa, Yusuke Kageyama, Zulzikry Hafiz Abu Bakar, Ken‐ichi Mukaisho, Ikuo Tooyama · 2023 · ACTA HISTOCHEMICA ET CYTOCHEMICA
  15. 17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson’s disease are associated with LRRC37A/2 expression in astrocytes
    KR Bowles, DA Pugh, Y Liu, Alan Edward Renton, Sara Bandrés‐Ciga, Ziv Gan‐Or, P Heutink, A Siitonen, S Bertelsen, Jonathan D. Cherry et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  16. Identification of Parkinson PACE subtypes and repurposing treatments through integrative analyses of multimodal clinical progression, neuroimaging, genetic, and transcriptomic data
    Chang Su, Yu Hou, Jielin Xu, Zhenxing Xu, Jie Xu, Matthew Brendel, Jacqueline R. M. A. Maasch, Zilong Bai, Haotan Zhang, Yingying Zhu et al. · 2021 · medRxiv
  17. Flavonoids and Saponins from Two Chenopodium Species (C. foliosum Asch. and C. bonus-henricus L.)—Preliminary Evaluation for hMAO-A/B, Neuroprotective Activity, and Validated UHPLC-HRMS Quantification of Ethanolic Extract from C. foliosum
    Magdalena Kondeva-Burdina, Dona Panayotova, Paraskev T. Nedialkov, Zlatina K. Kokanova-Nedialkova · 2025 · Molecules
  18. Comparative analysis of progression milestones across Parkinson’s disease clinical, pathological, and data-driven subtypes: a 10-year follow-up
    Ahmed Negida, Nitai D. Mukhopadhyay, Brian D. Berman, Matthew J. Barrett · 2026 · npj Parkinson s Disease
  19. Microfluidic platform for understanding Parkinson’s disease and α-synuclein conformation
    Pavel P. Tregub, Georgy M. Zembatov, Eugenia Namiot, Kolotyeva Natalia, Yurchenko Stanislav, Illarioshkin Sergey, Alla B. Salmina · 2025 · Translational Neurodegeneration
  20. Clinical correlates of a negative cerebrospinal fluid α-synuclein seed amplification assay result in Parkinson’s disease
    Andrea Mastrangelo, Isabel Wurster, Alice Ticca, Stefanie Lerche, Corrado Zenesini, Benjamin Röeben, Angela Mammana, Ann‐Kathrin Hauser, Edoardo Ruggeri, Christian Deuschle et al. · 2026 · npj Parkinson s Disease
  21. Molecular profiling of alpha-synuclein pathology and seeding activity in Parkinson’s disease
    Zeynep Bengisu Kaya, Danilyn Amerna, Ananya Susarla, Melina J. Lim, Maria Esperanza Bregendahl, Hiroaki Sekiya, Michael A. Deture, Owen A. Ross, Dennis W. Dickson, Suelen Lucio Boschen et al. · 2026 · Acta Neuropathologica
  22. Rewiring Neuroimmunity: Nanoplatform Innovations for CNS Disease Therapy
    Muhammad Usman Akbar, Weiwei Guo, Xin Ming Shen, Yimeng Fang, Yilin Liu, Peng‐Yuan Wang, Roey Elnathan, Yaping Chen · 2025 · Advanced Therapeutics
  23. Potentials of autophagy enhancing natural products in the treatment of Parkinson disease
    Taiwo Grace Olubodun-Obadun, Ismail Ogunbayode Ishola, Olufunmilayo Olaide Adeyemi · 2021 · Drug Metabolism and Personalized Therapy
  24. Blackberry (Morus nigra) usage in Parkinson's disease
    Yasir Hasan Siddique, Gulshan Ara, Falaq Naz · 2023 · Elsevier eBooks
  25. Impact of motor dysfunction on neuropsychiatric symptom profile in patients with autopsy-confirmed Alzheimer’s disease
    Jacob S. Shaw, Lisa N. Richey, Mia K. Gifford, Michael J. C. Bray, Aaron I. Esagoff, Paul B. Rosenberg, Matthew E. Peters · 2024 · International Review of Psychiatry
  26. Breaking bad aggregates: How a DNA aptamer cleans up Parkinson’s disease
    Maxim V. Berezovski · 2024 · Molecular Therapy — Nucleic Acids
  27. Template-Oriented Multi-task Sparse Low-Rank Learning for Parkinson’s Diseases Diagnosis
    Zihao Chen, Haijun Lei, Yujia Zhao, Zhongwei Huang, Xiaohua Xiao, Yi Lei, Ee-Leng Tan, Baiying Lei · 2020 · Lecture notes in computer science
  28. Molecular Imaging in Neurology
    Shankar Vallabhajosula · 2023 · Springer eBooks
  29. Predictive Analysis of Parkinson's Disease Using Machine Learning
    Harshitha Kamal Kannan, M R Pooja, Vinayakumar Ravi · 2025 · The Open Bioinformatics Journal
  30. Identifying Druggable Inflammatory Proteins Causally Contributing to Parkinson's Disease
    Ziyao Zhang, Hongbao Cao, Ancha V. Baranova, Fuquan Zhang · 2025 · Brain and Behavior
  31. Nutrition and Neuroinflammation
    Asiat Na’Allah, Abraham Olufemi Asuku, AbdulBasit AbdulRazaq, Owoola Azeezat Ambali, Mosunmola Busayo Oyeleke, Adeyemi Fatai Odetayo · 2025 · Nutritional neurosciences
  32. Effects and Mechanisms of Melatonin Receptor Agonist and Antagonist on Disease Progression in a 6-OHDA-Induced Parkinson’s Disease Rat Model
    Renxi Lin, Pengyang Liu, Weibin Lin, Jing Lin, Leyi Huang, Ling Lin · 2025 · Journal of Integrative Neuroscience
  33. Amelioration of 6-OHDA-Induced Parkinson’s Symptoms in Zebrafish Larvae by an Almond Skin Acetonic Extract
    Patrícia Carneiro, Patricia Pais, Ivo Vaz Oliveira, Sandra Mariza Monteiro, Carlos A. S. Venâncio, Luís Manuel Félix · 2026 · International Journal of Molecular Sciences
  34. Cerebellar oligodendrocytic α-synuclein pathology and dentate nucleus neuronal hypertrophy in Parkinson’s disease
    Diego Iacono, Hui Peng, John‐Paul Bouffard, Roger Kurlan · 2026 · Scientific Reports
  35. The Gut-Brain Axis: A Critical Link between Type 2 Diabetes and Parkinson’s disease
    Najlaa H. Almohmadi, Hayder M. Al‐kuraishy, Khulood S. Hussein, Arwa Turkistani, Fatimah M. Yousef, Ali Ismail Al-Gareeb, Ahmed M Abdelaziz, Yaser Hosny Ali Elewa, Gaber El‐Saber Batiha · 2026 · Probiotics and Antimicrobial Proteins
  36. p53 regulates mitochondrial function and alpha-synuclein aggregation in Parkinson's disease
    Kaiying Hou, Jialin Chen, Yuxin Xie, Tingting Liu, Jiaying Li, Chong Meng, 牛冬雪, Meiyan Xian, Jingwen Li, Chaoyang Zhu et al. · 2026 · Journal of Biological Chemistry
  37. Machine Learning and Deep Learning for Neurological Disease Analysis: A Systematic Review Across Five Major Disorders
    Kazi Nur Uddin, Partho Ghose, Ebrima Njie, Nafees Mahmood, Niloy Kumar, Md Azijul Haque, Dr. Loveleen Gaur, Aimin Li, Saurav Mallik · 2026 · Neuroscience
  38. Effects of binary dance rhythm compared with quaternary dance rhythm in fatigue, sleep, and daily sleepiness of individuals with Parkinson's disease: A randomized clinical trial
    Jéssica Moratelli, Kettlyn Hames Alexandre, Leonessa Boing, Alessandra Swarowsky, Clynton Lourenço Corrêa, Adriana Coutinho de Azevedo Guimarães · 2022 · Motriz Revista de Educação Física
  39. Immune Booster Property of Epigallocatechin-3-Gallate and Catechin
    Leidy Johana Valencia‐Hernández, Juan A. Ascacio‐Valdés, Jorge E. Wong‐Paz, Haroon Zaman Khan, Cristóbal N. Aguilar · 2022 · Springer eBooks
  40. Structural magnetic resonance imaging in Parkinson disease with freezing of gait: A systematic review of literature
    Ade Pambayu Suharto, Anggraini Dwi Sensusiati, Muhammad Hamdan, Dewi Setyaning Bastiana · 2023 · Journal of Neurosciences in Rural Practice
  41. Histogram analysis of diffusion kurtosis imaging of deep brain nuclei in Parkinson's disease with different motor subtypes
    J. Wang, Q. Bi, W. Gong, H. Zhang, M. Deng, Lujia Chen, B. Wang · 2023 · Clinical Radiology
  42. Therapie – Quo vadis Neurodegeneration?
    Jonathan Vöglein, Johannes Levin, Günter U. Höglinger · 2023 · Der Nervenarzt
  43. Reorganization of motor network in patients with Parkinson's disease after deep brain stimulation
    Bei Luo, Lei Chang, Chang Qiu, Wenwen Dong, Liang Zhao, Yue Lu, Jian Sun, Jiuqi Yan, Xiang Wei, Jun Yan et al. · 2024 · CNS Neuroscience & Therapeutics
  44. L’intestin, lanceur d’alerte, dans les prémices de la maladie de Parkinson
    Doriane Hazart, Malvyne Rolli‐Derkinderen, Brigitte Delhomme, Pascal Derkinderen, Martin Oheim, Clément Ricard · 2024 · médecine/sciences
  45. History of symptoms consistent with REM sleep behavior disorder in a population with Parkinson's Disease
    Viviane Akemi Kakazu, Dalva Rollemberg Poyares, Sérgio Tufik, Henrique Ballalai Ferraz, Gabriel Natan Pires · 2024 · Sleep Medicine
  46. Protein aggregation in health and disease: A looking glass of two faces
    Guilherme Caldas de Andrade, Michelle F. Mota, Dinarte N Moreira-Ferreira, Jerson Lima Silva, Guilherme A. P. de Oliveira, Mayra A. Marques · 2024 · Advances in protein chemistry and structural biology
  47. Flavonoids and related compounds targeting pathomechanisms of Parkinson’s Disease – from bench to bedside: A focused review of current perspectives, clinical trial outcomes, and future directions
    Monika Figura, Amos A. Fatokun · 2025 · Phytomedicine Plus
  48. Do we need to redefine the advanced stage in Parkinson’s disease?
    Ángel Sesar, Gustavo Fernández‐Pajarín, Begoña Ares, Alfonso Castro · 2021 · Revista de Fomento Social
  49. A different view on the pathophysiology of Parkinson’s disease: a descendent neurochemical hypothesis?
    Burak Yuluğ, Mehmet Ozansoy, Şeyda Çankaya · 2019 · Neural Regeneration Research
  50. Research Progress on Polymorphisms and Phenotypic Characteristics of Parkinson’s Disease-Related Genes in Chinese Population
    书娟 李 · 2020 · Advances in Clinical Medicine
  51. Sleep quality, REM sleep behavior disorder and daytime sleepiness in adults with and without Parkinson's
    Andrea Díaz Pacheco, Jesús Moo Estrella · 2021 · Archivos de Neurociencias
  52. Registered report: Does transcranial direct current stimulation of the primary motor cortex improve implicit motor sequence learning in Parkinson's disease?
    Mahyar Firouzi, Kris Baetens, Eva Swinnen, Chris Baeken, Frank Van Overwalle, Natacha Deroost · 2021 · Journal of Neuroscience Research
  53. Las empresas informativas en la Europa sin fronteras
    Alfonso Sánchez‐Tabernero, Carmelo Garitaonandia Garnacho · 1992 · Dialnet (Universidad de la Rioja)
  54. Early Detection of Parkinson’s Disease as a Pre-diagnosis Tool Using Various Classification Techniques on Vocal Features
    Vaibhaw, Pratik Ranjan Behera, Vaibhav Bal, Jay Sarraf · 2022 · Lecture notes in computer science
  55. Parkinson's Disease: An Overview and Role of Glutamate and its Receptors: Glutamate receptor based therapy as an alternate way to treat Parkinson's
    Divya Yadav, Pravir Kumar · 2021 · International Conference on Information Systems and Computer Networks (ISCON)
  56. β-carotene Has the Neuroprotective Effects in Parkinson's Disease by Regulating Mitochondrial Apoptotic Pathway Genes
    Behdokht Jamali, Maliheh Entezari, Nahid Babaei, Mehrdad Hashemi, Mansoor Heidari · 2022 · Journal of Human Genetics and Genomics
  57. Electroencephalographic-Based Functional Connectivity Networks of Visual Hallucinations and Visuospatial Dysfunctions in Parkinson’s Disease
    Kaoru Kinugawa, Tomoo Mano, Tsunenori Takatani, Akira Kido, Kazuma Sugie · 2022 · European Neurology
  58. Efeitos motores da rotenona em zebrafish como modelo animal da doença de Parkinson-like
    André Lucas Corrêa de Andrade, Renatta Priscilla Ferreira Silva, Jadson Freitas da Silva, Pabyton Gonçalves Cadena · 2022 · Revista Eletrônica Acervo Saúde
  59. Diseases with the highest mortality
    Sara Avilés‐Gaxiola, Marilyn Shomara Criollo-Mendoza, Melissa García-Carrasco, Erick Paul Gutiérrez‐Grijalva, Israel García-Aguiar, J. Basilio Heredia · 2023 · Elsevier eBooks
  60. TiO2-Nanowired Delivery of Chinese Extract of Ginkgo biloba EGb-761 and Bilobalide BN-52021 Enhanced Neuroprotective Effects of Cerebrolysin Following Spinal Cord Injury at Cold Environment
    Lars Wiklund, Aruna Sharma, Dafin Fior Muresanu, Zhiqiang Zhang, Cong Li, Z. Ryan Tian, Anca Dana Buzoianu, José Vicente Lafuente, Ala Nozari, Lianyuan Feng et al. · 2023 · Advances in neurobiology
  61. Replication of chromosomal loci involved in Parkinson’s disease: A quantitative synthesis of GWAS
    Dimitrios Rikos, Vasileios Siokas, Tatyana I. Burykina, Nikolaos Drakoulis, Efthimios Dardiotis, Elias Zintzaras · 2021 · Toxicology Reports
  62. RIT2 reduces LRRK2 kinase activity and protects against alpha-synuclein neuropathology
    Julia Obergasteiger, Anne-Marie Castonguay, Giulia Frapporti, Evy Lobbestael, Veerle Baekelandt, Andrew A. Hicks, Peter Paul Pramstaller, Claude Gravel, Corrado Corti, Martin Lévesque et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  63. Muscle bursting and corticomotor excitability index impaired impulse control in Parkinson’s disease
    Aliya C. M. Warden, Craig J. McAllister, Damian Cruse, Ben Wright, Hayley J. MacDonald · 2025 · medRxiv
  64. The microRNAs ( miRs ) overexpressing mesenchymal stem cells ( MSCs ) therapy in neurological disorders; hope or hype
    Sulieman Ibraheem Shelash Al‐Hawary, Anas Yahya Ali, Yasser Fakri Mustafa, Ria Margiana, Shamsutdinova Maksuda Ilyasovna, Montather F. Ramadan, Sami G. Almalki, Marim Alwave, Safa Alkhayyat, Ali Alsalamy · 2023 · Biotechnology Progress
  65. Validity of the Vienna Visuo-Constructional Test 3.0-Screening, the Mini-Mental State Examination, and the Clock Drawing Test for Diagnosing Parkinson’s Disease
    Reiko Alice Fok, Sonja Zehetmayer, Christof Brücke, Johann P. Lehrner · 2023 · Zeitschrift für Neuropsychologie
  66. Basal Ganglia Diseases
    Sephira G. Ryman, Kathleen L. Poston · 2024 · Oxford University Press eBooks
  67. Identification of electromyographic patterns of bradykinesia in patients with Parkinson's disease
    Nikita Kozulin, Anastasiya Migulina, Denis Mokrushin, Gurgen A. Soghoyan, Aleksandr Artemenko, Биктимиров Артур Рамилевич · 2024 · Heliyon
  68. Substantia nigra alterations in mice modeling Parkinson’s disease
    I. N. Rozhkova, S. V. Okotrub, Eugeny Yu. Brusentsev, T. A. Rakhmanova, D. A. Lebedeva, V. S. Kozeneva, N. A. Shavshaeva, Н. В. Хоцкин, Sergei Ya Amstislavsky · 2024 · Vavilov Journal of Genetics and Breeding
  69. Neurodegenerative Disorder: An Overview
    Monika Verma, Sangeeta Shukla, Sadhana Shrivastava, Nidhi Puranik · 2025 · Springer eBooks
  70. Revolutionizing Parkinson’s Disease Treatment with Nanotechnology: A Focus on Lipid Nanoparticles
    Sivane Sunilkumar, G. Ariharasivakumar · 2025
  71. The Internal Ribosome Entry Site in Circular RNAs
    Queenie Fernandes, Zeenath Safira K. M. Yoosuf, Sarra Mestiri, Laila Assami, Karama Makni‐Maalej, Shahab Uddin M.S., Maysaloun Merhi, Said Dermime · 2025 · Advances in experimental medicine and biology
  72. MPP+ induces α-synuclein oligomerization and neurite impairment by disrupting mitochondrial function and Akt signaling, with apigenin emerging as a potential neuroprotective agent
    Ratchaneekorn Reudhabibadh, Nidanut Champoochana, Zulkiflee Kuedo, Peungchaleoy Thammanichanon, Pilaiwanwadee Hutamekalin, Thunwa Binlateh · 2025 · Food and Chemical Toxicology
  73. Exploring the applications of molecularly imprinted polymers in drug delivery to the nervous system
    Hooman Pourbala, Fateme Peyvand, Sepehr Izadi, Shahin Jafari Ashtiani, Dorsan Rabbanian, Niki Pouyanfar, Kamran Banan, Mohammad‐Ali Shahbazi, Mehrdad Faizi, Fatemeh Ghorbani‐Bidkorbeh · 2025 · Journal of Drug Delivery Science and Technology
  74. Assessment of [125I]a-Bungarotoxin Binding to a7 Nicotinic Acetylcholinergic Receptors in Hippocampus-Subiculum of Postmortem Human Parkinson’s Disease Brain
    Fariha Karim, Allyson Ngo, Titus E. Tucker, Ashlee D. L. Coronel, Jogeshwar Mukherjee · 2025 · Biomolecules
  75. Muscle bursting and corticomotor excitability mark impaired impulse control in Parkinson’s disease
    Aliya C. M. Warden, Craig J. McAllister, Damian Cruse, Ben L. C. Wright, Hayley J. MacDonald · 2025 · npj Parkinson s Disease
  76. MOF and COF-based drug delivery system for Parkinson's disease: Mechanism, future and development of artificial intelligence
    Chun-Yue Shi, Yan Liang, Yusheng Wang, Xinyi Zhang, Aparna Kushwaha, Abhinav Kumar, Jun Wang, Qin Ouyang, Yong Huang · 2025 · Materials Today Chemistry
  77. mGluR4–NPDC1 complex mediates α-synuclein fibril-induced neurodegeneration
    Azucena Pérez‐Cañamás, Mingming Chen, Leire Almandoz-Gil, Nabab Khan, Si Jie Tang, Allyson Ho, Erik C. Gunther, Stephen M. Strittmatter · 2025 · Nature Communications
  78. Current Neuroimaging Modalities to Distinguish Parkinson’s Disease from its Mimics: Imaging Features and Implications for Clinical Practice
    M. M. Gad, Francis Deng, Jannik Prasuhn, Licia Luna · 2026 · The Neuroradiology Journal
  79. Molecular analysis of mitochondrial complex I in the levodopa short duration response in Parkinson's disease
    Ana Gabrielle Bispo, Felipe Gouvêa de Souza, Matheus Caetano Epifane-de-Assunção, Camille Sena-dos-Santos, Gustavo Barra Matos, Dafne Dalledone Moura, Gracivane Lopes Eufraseo, Caio Santos Silva, Gilderlanio Santana de Araújo, Ândrea Ribeiro‐dos‐Santos et al. · 2026 · Parkinsonism & Related Disorders
  80. Targeting NME3 to Restore Mitochondrial Fission‐Fusion Balance Defines a Novel Disease‐Modifying Strategy for Parkinson's Disease
    Qiao Chen, Xiang‐Qi Hu, Shen‐Han Xu, Meng‐Fan Yao, Jiayi Liu, Lei Cao · 2026 · CNS Neuroscience & Therapeutics
  81. Identification of platelet-derived biomarker in a cohort of Parkinson's disease
    Zhao-Ying Dong, Yu Xiang, Ling Wang, Yu Ai, Xin-Yi Du, Yuan-Yuan Sun, Zhi-Hao Lin, Tong-Fei Liu, Jian-Bo Pan, Jianwen Deng et al. · 2026 · Genes & Diseases
  82. Copper Overload Affects α‐Synuclein Clearance Mechanisms in a Parkinson's Disease In Vitro Model
    Debora Musarò, Marina Damato, Chiara Coppola, Marco Greco, Michele Maffia · 2026 · Advanced Biology
  83. Dual Neuroprotective and Nephroprotective Effects of Mucuna pruriens, Moringa oleifera, and Silybum marianum (Milk Thistle) via Modulation of PI3K/AKT/mTOR and Nrf2/NF-κB Pathways in a Murine Comorbid PD–AKI Model
    Iman Al Housseini, Hoda Dakdouk, Hadi El Natour, Jamilah Borjac · 2026 · International Journal of Molecular Sciences
  84. White matter lesions disrupt cholinergic pathways important for cognition in Parkinson’s disease
    Giulia Carli, Taylor Brown, Fotini Michalakis, Abigail M Biddix, Stiven Roytman, Robert Vangel, August Van Hout, Prabesh Kanel, Peter J. H. Scott, Roger L. Albin et al. · 2026 · Brain
  85. Biomarcatori periferici nelle malattie neurodegenerative: una rassegna sui seed amplification assays
    Federico Angelo Cazzaniga, Fabio Moda · 2026 · Biochimica Clinica
  86. Application of Automated Data Analytics and Machine Learning to Develop Explainable Objective Markers for Differential Assessment of Progressive Motor Speech Disorders in Neurodegenerative Diseases
    Katherine Marx, Lindsey Heidrick, Panying Rong · 2026 · AI in Neurology
  87. Neuroprotective effect of mesenchymal stem cell-derived miR-143-3p on dopaminergic neurons via the TLR3/NF-κB/p53 signaling pathway
    Jing Sun, Tian Wang, Chen Qiu, TT Li, Peng Wang, Tatyana Matveeva, Tanner Boyd, Q B Tang, Jun Xue, Lu Su et al. · 2026 · Stem Cell Research & Therapy
  88. Herbal nanoparticles in the treatment of neurodegeneration: from molecular mechanisms to therapeutic translation
    D. Mittal, P. Solanki, G. K. Jain, V. Jhawat, Prashant Kesharwani, Rohit Dutt, Saahil Arora, R. Singh · 2026 · 3 Biotech
  89. Relationship Between Braak and Clinical Stage in Autopsy-Confirmed Parkinson Disease
    Lazzaro di Biase, Pasquale Maria Pecoraro, Francesco Bugamelli, Martina Di Carluccio, Luca Marsili, Alberto Javier Espay · 2026 · Neurology
  90. The regulatory functions of the brain: From genome to organism
    M. V. Ugryumov · 2010 · Herald of the Russian Academy of Sciences
  91. Fighting Parkinson’s … and Winning: A memoir of my recovery from Parkinson’s Disease
    Marian W. Roman · 2018 · Issues in Mental Health Nursing
  92. Therapeutic Regime to Ameliorate Quality of Life in Patients with Parkinson’s Disease
    Nidhi Sharma, Manpreet Kaur, Anju Goyat, Priyanka Sharma, Adarsh Kumar Srivastav, Bimal Kumar Agrawal · 2021 · Physical & Occupational Therapy In Geriatrics
  93. Compensation strategies for gait impairment in Parkinson’s disease. Towards personalized gait rehabilitation
    Anouk Tosserams · 2023 · Radboud University Press eBooks
  94. Efficacy of Intravenous Paracetamol, Dexketoprofen, and Ibuprofen in Treating Headache Induced by Acute Migraine Attack
    Şerife Örnek, Atakan Yılmaz, Alten Oskay, Aykut Kemancı, Mehmet Ulutürk, Yeşim Kınacı Çimen, Ezgi Demirözoğul, Murat Seyit, Mert Özen, İbrahim Türkçüer · 2024 · Eurasian Journal of Emergency Medicine
  95. Management of Kampavata (Parkinson’s Disease) through Panchakarma: A Successful Case Study
    Sonia Mandal, Punam Gaurav Sawarkar, Varinder Singh, Shweta Dadarao Parwe, Gaurav Rajendra Sawarkar · 2024 · Journal of Pharmacology and Pharmacotherapeutics
  96. Sofalcone attenuates neurodegeneration in MPTP-induced mouse model of Parkinson’s disease by inhibiting oxidative stress and neuroinflammation
    Mulan Chen, Xin He, Yepeng Fan, Xia Lei, Zhifang Dong · 2024 · Molecular Biology Reports
  97. Part Two: Extracellular Vesicles as a Risk Factor in Neurodegenerative Diseases
    Laura Cristina Ceafalan, Octavian Costin Ioghen, Daciana Silvia Marta, Alina Liliana Constantin, Nicoleta Alexandru, Miruna Nemecz, Gabriela Tanko, Alexandru Filippi, Stefania Lucia Magda, Florina Maria Bojin et al. · 2019 · IntechOpen eBooks
  98. Avaliação do impacto de sintomas psiquiátricos na qualidade de vida em pacientes com doença de parkinson
    Rodrigo Cardoso de Matos, Gabriel de Almeida Rios, Talyta Cortez Grippe · 2021 · Programa de Iniciação Científica - PIC/UniCEUB - Relatórios de Pesquisa
  99. Relevancia del metabolismo del folato en el contexto de enfermedades neurodegenerativas
    Yasnay Jorge Saínz, Dany a. Cuello Almarales, Luis Enrique Almaguer Mederos · 2021 · Revista Habanera de Ciencias Médicas
  100. Fluorescence detection of amyloid deposits in human tissues using histochemical dyes
    В. В. Гусельникова, Д. А. Суфиева, Daria L. Tsyba, Dmitriy E. Korzhevsky · 2021 · Bulletin of Russian State Medical University